0001104659-20-057631.txt : 20200506
0001104659-20-057631.hdr.sgml : 20200506
20200506213141
ACCESSION NUMBER: 0001104659-20-057631
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200504
FILED AS OF DATE: 20200506
DATE AS OF CHANGE: 20200506
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Francomano Robert
CENTRAL INDEX KEY: 0001797467
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35619
FILM NUMBER: 20854282
MAIL ADDRESS:
STREET 1: C/O STEMLINE THERAPEUTICS, INC.
STREET 2: 750 LEXINGTON AVENUE, 11TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: STEMLINE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001264587
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450522567
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
STREET 2: ELEVENTH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 646-502-2311
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
a4.xml
4
X0306
4
2020-05-04
0
0001264587
STEMLINE THERAPEUTICS INC
STML
0001797467
Francomano Robert
C/O STEMLINE THERAPEUTICS, INC.
750 LEXINGTON AVENUE, ELEVENTH FLOOR
NEW YORK
NY
10022
0
1
0
0
Chief Commercial Officer
Common Stock
2020-05-04
4
S
0
272
11.51
D
197658
D
In connection with the vesting of 1,878 shares on May 2, 2020 a total of 272 shares were sold by the Company on May 4, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
Reflects the weighted average sale price. The range of prices for the shares sold on May 4, 2020 was $11.81 to $12.02. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
Of the shares listed, 144,425 shares are restricted stock.
/s/ Kenneth Hoberman, Attorney-in-Fact
2020-05-06